E2F Family of Transcription Factors: Driven By Complex Cellular Processes and Potential Drug Targets

Target Name: E2F Transcription Factor

NCBI ID: P10242

E2F Transcription Factor

Other Name(s): E2F

E2F Family of Transcription Factors: Driven By Complex Cellular Processes and Potential Drug Targets

The E2F transcription factor (nonspecified subtype) (E2F) is a key regulator of gene expression and has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Despite its significant impact on cellular biology, the precise mechanism of its action and the specific targets it interacts with are not well understood.

The E2F family of transcription factors is a subset of the TAF/CREB-CBP complex, which are known to play a crucial role in regulating gene expression and cell fate. The E2F subfamily consists of four proteins: E2F1, E2F2, E2F3, and E2F4 , which differ in their N-terminal and C-terminal regions.

E2F1, the first and most well-studied subunit of the E2F family, contains a N-terminal domain with sequence homology to the protein p120, a conserved transmembrane protein that is involved in various cellular processes, including cell signaling and protein-protein interactions ( 1). The C-terminal region of E2F1 contains a sequence that is similar to the N-terminal region of E2F2 and is involved in the formation of a protein-protein interaction.

E2F2, the second subunit of the E2F family, contains a N-terminal domain with sequence homology to the protein p130, a conserved transmembrane protein that is involved in various cellular processes, including cell signaling and protein-protein interactions. The C -terminal region of E2F2 contains a sequence that is similar to the N-terminal region of E2F3 and is involved in the formation of a protein-protein interaction.

E2F3, the third subunit of the E2F family, contains a N-terminal domain with sequence homology to the protein p140, a conserved transmembrane protein that is involved in various cellular processes, including cell signaling and protein-protein interactions. The C -terminal region of E2F3 contains a sequence that is similar to the N-terminal region of E2F4 and is involved in the formation of a protein-protein interaction.

E2F4, the fourth and most well-studied subunit of the E2F family, contains a N-terminal domain with sequence homology to the protein p150, a conserved transmembrane protein that is involved in various cellular processes, including cell signaling and protein-protein interactions ( 7). The C-terminal region of E2F4 contains a sequence that is similar to the N-terminal region of E2F1 and is involved in the formation of a protein-protein interaction.

Despite the complexity of the E2F family of transcription factors, the precise mechanism of their action and the specific targets they interact with remains an enigma. The studies on E2F have provided valuable insights into the regulation of gene expression and the role of transcription factors in cellular biology.

Recent studies have identified potential drug targets for the E2F family of transcription factors. For example, E2F has been shown to be a potential drug target for various diseases, including neurodegenerative diseases, cancer, and developmental disorders.

In neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, E2F has been shown to play a role in the regulation of neurotransmitter release and the maintenance of neuronal excitability. E2F has also been shown to be involved in the regulation of protein- protein interactions, which are critical for the regulation of cellular signaling.

In cancer, E2F has also been shown to play a role in the regulation of gene expression and the maintenance of cell proliferation. E2F has also been shown to be involved in

Protein Name: E2F Transcription Factor (nonspecified Subtype)

The "E2F Transcription Factor Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about E2F Transcription Factor comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets